China Ophthalmology Focus eyes Asia market

Spun out from Lee’s in May and aiming for its first NDA submissions next year, China Ophthalmology Focus is already looking ahead to a Hong Kong IPO and an expansion into other Asian markets with its portfolio of novel and generic ophthalmology products.

The company spun out of Lee’s with a $50 million series A round and 21 programs in development, including nine innovative compounds and 12 generics that span dry eye diseases, glaucoma, wet age-related macular degeneration (AMD), corneal diseases and inflammatory diseases of the eye. ...